Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
SAN CARLOS, Calif., October 10, 2007 /PRNewswire-FirstCall/ -- Nektar Therapeutics announced today that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics in San Francisco, California on October 25, 2007. The presentations will highlight new results from preclinical trials of NKTR-102 in mouse models of colorectal, lung and breast cancers. NKTR-102 is a PEGylated form of irinotecan created using Nektar's innovative small molecule PEGylation technology platform and is in Phase 1 clinical development for the treatment of solid tumors.
In preclinical studies presented at ECCO 14 in September, NKTR-102 substantially suppressed tumor growth in an irinotecan-resistant mouse colorectal tumor model, while irinotecan-treated groups did not show a statistically significant decrease in tumor growth compared to controls. Further, administration of NKTR-102 resulted in a significantly improved pharmacokinetic profile for the active metabolite of irinotecan as compared to treatment with irinotecan.
"The studies for NKTR-102 continue to indicate that Nektar's small molecule PEGylation technology can be a powerful platform for improving chemotherapeutic agents," Tim Riley, Ph.D., Vice President of PEGylation Research at Nektar. "The new preclinical data in colorectal, lung and breast tumor models also highlights the promise of NKTR-102 to serve as a potentially new and powerful therapy in multiple solid tumor settings."
Two poster presentations are scheduled:
October 25, 2007 - 12:30 PM - 2:00 PM (PT); 5:30 - 7:30 PM (PT)
Poster Session C -- AACR-NCI-EORTC International Conference on Molecular
Targets and Therapeutics at Moscone Center West in San Francisco,
California.
-- #C10 -- A poster presentation of preclinical data focused on tumor
growth inhibition of NKTR-102 in mouse xenograft models of colorectal,
lung and breast cancer;
-- #C157 -- A poster presentation of preclinical data focused on the
pharmacokinetics and pharmacodynamics of the active metabolite of
irinotecan following administration of NKTR-102 in mouse xenograft models
of lung and colorectal cancer.
The AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics Conference is an annual meeting of the American Association of Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC). More information
about the conference is available on the American Association of Cancer Research's website at:
http://www.aacr.org/home/scientists/meetings--workshops/molecular-targets-
and-cancer-therapeutics.aspx
About NKTR-102
Nektar is developing NKTR-102, a PEGylated form of irinotecan, which was invented by Nektar using its world-leading small molecule PEGylation technology platform. The product is currently in Phase 1 clinical development. Irinotecan is an important chemotherapeutic agent used for the treatment of solid tumors, including colorectal and lung cancers. By applying Nektar's small molecule PEGylation technology to irinotecan, NKTR-102 may prove to be a more powerful and tolerable anti-tumor agent.
Posted: October 2007
